Scientific article
Case report
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma
Published inHaematologica, vol. 103, no. 1, p. e39-e41
Publication date2018-01
First online date2017-11-02
Keywords
- Aged
- Antineoplastic Combined Chemotherapy Protocols / adverse effects
- Antineoplastic Combined Chemotherapy Protocols / therapeutic use
- Biomarkers
- Biopsy
- Combined Modality Therapy
- Histiocytic Sarcoma / diagnosis
- Histiocytic Sarcoma / drug therapy
- Histiocytic Sarcoma / metabolism
- Humans
- Imatinib Mesylate / administration & dosage
- Immunohistochemistry
- Immunophenotyping
- Male
- Molecular Targeted Therapy
- Positron Emission Tomography Computed Tomography
- Pyridones / administration & dosage
- Pyrimidinones / administration & dosage
- Retreatment
- Symptom Assessment
- Treatment Outcome
Affiliation entities Not a UNIGE publication
Citation (ISO format)
VORUZ, Sophie et al. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. In: Haematologica, 2018, vol. 103, n° 1, p. e39–e41. doi: 10.3324/haematol.2017.179150
Main files (1)
Article (Published version)
Identifiers
- PID : unige:190579
- DOI : 10.3324/haematol.2017.179150
- PMID : 29097496
- PMCID : PMC5777214
Additional URL for this publicationhttps://haematologica.org/article/view/8337
Journal ISSN0390-6078
